Anaplastic lymphoma kinase: Signalling in development and disease

Biochemical Journal

Volumn 420, Issue 3, 2009, Pages 345-361

  Palmer, Ruth H ^a   Vernersson, Emma ^a   Grabbe, Caroline ^a   Hallberg, Bengt ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Anaplastic large cell lymphoma (ALCL); Anaplastic lymphoma kinase (ALK); Extracellular signal regulated kinase (ERK); Inflammatory myofibroblastic tumour (IMT); Midkine; Neuroblastoma; Non small cell lung cancer (NSLCL); Pleiotrophin

Indexed keywords

ANAPLASTIC LARGE CELL LYMPHOMA (ALCL); ANAPLASTIC LYMPHOMA KINASE (ALK); EXTRACELLULAR-SIGNAL-REGULATED KINASE (ERK); INFLAMMATORY MYOFIBROBLASTIC TUMOUR (IMT); MIDKINE; NEUROBLASTOMA; NON-SMALL CELL LUNG CANCER (NSLCL); PLEIOTROPHIN;

AMINO ACIDS; AMPLIFICATION; BIOLOGICAL ORGANS; CELL PROLIFERATION; ULTRASONIC DELAY LINES;

TUMORS;

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 7 HYDROXYSTAUROSPORINE; ANAPLASTIC LYMPHOMA KINASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; ERLOTINIB; GEFITINIB; HYBRID PROTEIN; IMATINIB; NUCLEOPHOSMIN; NVP TAE 684; ONCOPROTEIN; PREDNISONE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TAE 864; TRASTUZUMAB; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CAENORHABDITIS ELEGANS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME REARRANGEMENT; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DROSOPHILA MELANOGASTER; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME STRUCTURE; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; LARGE CELL LYMPHOMA; LIGAND BINDING; LUNG NON SMALL CELL CANCER; MAMMAL; NEUROBLASTOMA; NONHUMAN; PLASMA CELL GRANULOMA; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; ZEBRA FISH;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MODELS, BIOLOGICAL; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

ECHINODERMATA;

EID: 66949152073     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20090387     Document Type: Review

References (237)

1. Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L. and Look, A. T. (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281-1284
2. Shiota, M., Fujimoto, J., Semba, T., Satoh, H., Yamamoto, T. and Mori, S. (1994) Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9, 1567-1574
3. Iwahara, T., Fujimoto, J., Wen, D., Cupples, R., Bucay, N., Arakawa, T., Mori, S., Ratzkin, B. and Yamamoto, T. (1997) Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14, 439-449
4. Morris, S. W., Naeve, C., Mathew, P., James, P. L., Kirstein, M. N., Cui, X. and Witte, D. P. (1997) ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 14, 2175-2188
5. Loren, C. E., Scully, A., Grabbe, C., Edeen, P. T., Thomas, J., McKeown, M., Hunter, T. and Palmer, R. H. (2001) Identification and characterization of DAlk: a novel Drosophila melanogaster RTK which drives ERK activation in vivo. Genes Cells 6, 531-544
6. Stoica, G. E., Kuo, A., Aigner, A., Sunitha, I., Souttou, B., Malerczyk, C., Caughey, D. J., Wen, D., Karavanov, A., Riegel, A. T. and Wellstein, A. (2001) Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J. Biol. Chem. 276, 16772-16779
7. Daly, N. L., Scanlon, M. J., Djordjevic, J. T., Kroon, P. A. and Smith, R. (1995) Three-dimensional structure of a cysteine-rich repeat from the low-density lipoprotein receptor. Proc. Natl. Acad. Sci. U.S.A. 92, 6334-6338
8. Fass, D., Blacklow, S., Kim, P. S. and Berger, J. M. (1997) Molecular basis of familial hypercholesterolaemia from structure of LDL receptor module. Nature 388, 691-693
9. Beckmann, G. and Bork, P. (1993) An adhesive domain detected in functionally diverse receptors. Trends Biochem. Sci. 18, 40-41
10. Loren, C. E., Englund, C., Grabbe, C., Hallberg, B., Hunter, T. and Palmer, R. H. (2003) A crucial role for the Anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster. EMBO Rep. 4, 781-786
11. Bai, R. Y., Dieter, P., Peschel, C., Morris, S. W. and Duyster, J. (1998) Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-γ to mediate its mitogenicity. Mol. Cell. Biol. 18, 6951-6961
12. Donella-Deana, A., Marin, O., Cesaro, L., Gunby, R. H., Ferrarese, A., Coluccia, A. M., Tartari, C. J., Mologni, L., Scapozza, L., Gambacorti-Passerini, C. and Pinna, L. A. (2005) Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity. Biochemistry 44, 8533-8542
13. Tartari, C. J., Gunby, R. H., Coluccia, A. M., Sottocornola, R., Cimbro, B., Scapozza, L., Donella-Deana, A., Pinna, L. A. and Gambacorti-Passerini, C. (2008) Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J. Biol. Chem. 283, 3743-3750
14. Englund, C., Loren, C. E., Grabbe, C., Varshney, G. K., Deleuil, F., Hallberg, B. and Palmer, R. H. (2003) Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion. Nature 425, 512-516
15. Lee, H. H., Norris, A., Weiss, J. B. and Frasch, M. (2003) Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers. Nature 425, 507-512
16. Stute, C., Schimmelpfeng, K., Renkawitz-Pohl, R., Palmer, R. H. and Holz, A. (2004) Myoblast determination in the somatic and visceral mesoderm depends on Notch signalling as well as on milliways [mili(Alk)] as receptor for Jeb signalling. Development 131, 743-754
17. Klapper, R., Stute, C., Schomaker, O., Strasser, T., Janning, W., Renkawitz-Pohl, R. and Holz, A. (2002) The formation of syncytia within the visceral musculature of the Drosophila midgut is dependent on duf, sns and mbc. Mech. Dev. 110, 85-96
18. Martin, B. S., Ruiz-Gomez, M., Landgraf, M. and Bate, M. (2001) A distinct set of founders and fusion-competent myoblasts make visceral muscles in the Drosophila embryo. Development 128, 3331-3338
19. Weiss, J. B., Suyama, K. L., Lee, H. H. and Scott, M. P. (2001) Jelly belly: a Drosophila LDL receptor repeat-containing signal required for mesoderm migration and differentiation. Cell 107, 387-398
20. Varshney, G. K. and Palmer, R. H. (2006) The bHLH transcription factor Hand is regulated by Alk in the Drosophila embryonic gut. Biochem. Biophys. Res. Commun. 351, 839-846
21. Shirinian, M., Varshney, G., Loren, C. E., Grabbe, C. and Palmer, R. H. (2007) Drosophila anaplastic lymphoma kinase regulates Dpp signalling in the developing embryonic gut. Differentiation 75, 418-426
22. Bazigou, E., Apitz, H., Johansson, J., Loren, C. E., Hirst, E. M., Chen, P. L., Palmer, R. H. and Salecker, I. (2007) Anterograde Jelly belly and Alk receptor tyrosine kinase signaling mediates retinal axon targeting in Drosophila. Cell 128, 961-975
23. Liao, E. H., Hung, W., Abrams, B. and Zhen, M. (2004) An SCF-like ubiquitin ligase complex that controls presynaptic differentiation. Nature 430, 345-350
24. Reiner, D. J., Ailion, M., Thomas, J. H. and Meyer, B. J. (2008) C elegans anaplastic lymphoma kinase ortholog SCD-2 controls dauer formation by modulating TGF-β signaling. Curr. Biol. 18, 1101-1109
25. Ishihara, T., Iino, Y., Mohri, A., Mori, I., Gengyo-Ando, K., Mitani, S. and Katsura, I. (2002) HEN-1, a secretory protein with an LDL receptor motif, regulates sensory integration and learning in Caenorhabditis elegans. Cell 109, 639-649
26. Lopes, S. S., Yang, X., Muller, J., Carney, T. J., McAdow, A. R., Rauch, G. J., Jacoby, A. S., Hurst, L. D., Delfino-Machin, M., Haffter, P. et al. (2008) Leukocyte tyrosine kinase functions in pigment cell development. PLoS Genet. 4, e1000026
27. Vernersson, E., Khoo, N. K., Henriksson, M. L., Roos, G., Palmer, R. H. and Hallberg, B. (2006) Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr. Patterns 6, 448-461
28. Hurley, S. P., Clary, D. O., Copie, V. and Lefcort, F. (2006) Anaplastic lymphoma kinase is dynamically expressed on subsets of motor neurons and in the peripheral nervous system. J. Comp. Neurol. 495, 202-212
29. Degoutin, J., Brunet-de Carvalho, N., Cifuentes-Diaz, C. and Vigny, M. (2009) ALK (Anaplastic Lymphoma Kinase) expression in DRG neurons and its involvement in neuron-Schwann cells interaction. Eur. J. Neurosci. 29, 275-286
30. Pulford, K., Lamant, L., Morris, S. W., Butler, L. H., Wood, K. M., Stroud, D., Delsol, G. and Mason, D. Y. (1997) Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89, 1394-1404
31. Souttou, B., Carvalho, N. B., Raulais, D. and Vigny, M. (2001) Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J. Biol. Chem. 276, 9526-9531
32. Moog-Lutz, C., Degoutin, J., Gouzi, J. Y., Frobert, Y., Brunet-de Carvalho, N., Bureau, J., Creminon, C. and Vigny, M. (2005) Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J. Biol. Chem. 280, 26039-26048
33. Motegi, A., Fujimoto, J., Kotani, M., Sakuraba, H. and Yamamoto, T. (2004) ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J. Cell Sci. 117, 3319-3329.
34. Yang, H. L., Eriksson, T., Vernersson, E., Vigny, M., Hallberg, B. and Palmer, R. H. (2007) The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the Mouse ALK RTK. J. Exp. Zool. B Mol. Dev. Evol. 308, 269-282
35. Gouzi, J. Y., Moog-Lutz, C., Vigny, M. and Brunet-de Carvalho, N. (2005) Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells. J. Cell Sci. 118, 5811-5823
36. Degoutin, J., Vigny, M. and Gouzi, J. Y. (2007) ALK activation induces Shc and FRS2 recruitment: Signaling and phenotypic outcomes in PC12 cells differentiation. FEBS Lett. 581, 727-734
37. Chikamori, M., Fujimoto, J., Tokai-Nishizumi, N. and Yamamoto, T. (2007) Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation. Oncogene 26, 2950-2954
38. Piccinini, G., Bacchiocchi, R., Serresi, M., Vivani, C., Rossetti, S., Gennaretti, C., Carbonari, D. and Fazioli, F. (2002) A ligand-inducible epidermal growth factor receptor/anaplastic lymphoma kinase chimera promotes mitogenesis and transforming properties in 3T3 cells. J. Biol. Chem. 277, 22231-22239
39. Merenmies, J. and Rauvala, H. (1990) Molecular cloning of the 18-kDa growth-associated protein of developing brain. J. Biol. Chem. 265, 16721-16724
40. Tezuka, K., Takeshita, S., Hakeda, Y., Kumegawa, M., Kikuno, R. and Hashimoto-Gotoh, T. (1990) Isolation of mouse and human cDNA clones encoding a protein expressed specifically in osteoblasts and brain tissues. Biochem. Biophys. Res. Commun. 173, 246-251
41. Courty, J., Dauchel, M. C., Caruelle, D., Perderiset, M. and Barritault, D. (1991) Mitogenic properties of a new endothelial cell growth factor related to pleiotrophin. Biochem. Biophys. Res. Commun. 180, 145-151
42. Kovesdi, I., Fairhurst, J. L., Kretschmer, P. J. and Bohlen, P. (1990) Heparin-binding neurotrophic factor (HBNF) and MK, members of a new family of homologous, developmentally regulated proteins. Biochem. Biophys. Res. Commun. 172, 850-854
43. Tomomura, M., Kadomatsu, K., Matsubara, S. and Muramatsu, T. (1990) A retinoic acid-responsive gene, MK, found in the teratocarcinoma system. Heterogeneity of the transcript and the nature of the translation product. J. Biol. Chem. 265, 10765-10770
44. Vigny, M., Raulais, D., Puzenat, N., Duprez, D., Hartmann, M. P., Jeanny, J. C. and Courtois, Y. (1989) Identification of a new heparin-binding protein localized within chick basement membranes. Eur. J. Biochem. 186, 733-740
45. Stoica, G. E., Kuo, A., Powers, C., Bowden, E. T., Sale, E. B., Riegel, A. T. and Wellstein, A. (2002) Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J. Biol. Chem. 277, 35990-35998
46. Kadomatsu, K. and Muramatsu, T. (2004) Midkine and pleiotrophin in neural development and cancer. Cancer Lett. 204, 127-143
47. Muramatsu, T. (2002) Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J. Biochem. (Tokyo) 132, 359-371
48. Meng, K., Rodriguez-Pena, A., Dimitrov, T., Chen, W., Yamin, M., Noda, M. and Deuel, T. F. (2000) Pleiotrophin signals increased tyrosine phosphorylation of β-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase √ ζ. Proc. Natl. Acad. Sci. U.S.A. 97, 2603-2608
49. Maeda, N., Nishiwaki, T., Shintani, T., Hamanaka, H. and Noda, M. (1996) 6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase ζ/RPTPβ, binds pleiotrophin/ heparin-binding growth-associated molecule (HB-GAM). J. Biol. Chem. 271, 21446-21452
50. Nakanishi, T., Kadomatsu, K., Okamoto, T., Ichihara-Tanaka, K., Kojima, T., Saito, H., Tomoda, Y. and Muramatsu, T. (1997) Expression of syndecan-1 and -3 during embryogenesis of the central nervous system in relation to binding with midkine. J. Biochem. 121, 197-205
51. Raulo, E., Chernousov, M. A., Carey, D. J., Nolo, R. and Rauvala, H. (1994) Isolation of a neuronal cell surface receptor of heparin binding growth-associated molecule (HB-GAM). Identification as N-syndecan (syndecan-3). J. Biol. Chem. 269, 12999-13004
52. Muramatsu, H., Zou, K., Sakaguchi, N., Ikematsu, S., Sakuma, S. and Muramatsu, T. (2000) LDL receptor-related protein as a component of the midkine receptor. Biochem. Biophys. Res. Commun. 270, 936-941
53. Muramatsu, H., Zou, P., Suzuki, H., Oda, Y., Chen, G. Y., Sakaguchi, N., Sakuma, S., Maeda, N., Noda, M., Takada, Y. and Muramatsu, T. (2004) α4β1- and α6β1-integrins are functional receptors for midkine, a heparin-binding growth factor. J. Cell Sci. 117, 5405-5415
54. Bowden, E. T., Stoica, G. E. and Wellstein, A. (2002) Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J. Biol. Chem. 277, 35862-35868
55. Powers, C., Aigner, A., Stoica, G. E., McDonnell, K. and Wellstein, A. (2002) Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J. Biol. Chem. 277, 14153-14158
56. Kuo, A. H., Stoica, G. E., Riegel, A. T. and Wellstein, A. (2007) Recruitment of insulin receptor substrate-1 and activation of NF-κB essential for midkine growth signaling through anaplastic lymphoma kinase. Oncogene 26, 859-869
57. Lu, K. V., Jong, K. A., Kim, G. Y., Singh, J., Dia, E. Q., Yoshimoto, K., Wang, M. Y., Cloughesy, T. F., Nelson, S. F. and Mischel, P. S. (2005) Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J. Biol. Chem. 280, 26953-26964
58. Dirks, W. G., Fahnrich, S., Lis, Y., Becker, E., MacLeod, R. A. and Drexler, H. G. (2002) Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int. J. Cancer 100, 49-56
59. Mathivet, T., Mazot, P. and Vigny, M. (2007) In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? Cell. Signalling 19, 2434-2443
60. Mourali, J., Benard, A., Lourenco, F. C., Monnet, C., Greenland, C., Moog-Lutz, C., Racaud-Sultan, C., Gonzalez-Dunia, D., Vigny, M., Mehlen, P. et al. (2006) Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol. Cell. Biol. 26, 6209-6222
61. Perez-Pinera, P., Zhang, W., Chang, Y., Vega, J. A. and Deuel, T. F. (2007) Anaplastic lymphoma kinase is activated through the pleiotrophin/ receptor protein-tyrosine phosphatase β/ζ signaling pathway: an alternative mechanism of receptor tyrosine kinase activation. J. Biol. Chem. 282, 28683-28690
62. Fabri, L., Nice, E. C., Ward, L. D., Maruta, H., Burgess, A. W. and Simpson, R. J. (1992) Characterization of bovine heparin-binding neurotrophic factor (HBNF): assignment of disulfide bonds. Biochem. Int. 28, 1-9
63. Muramatsu, H., Inui, T., Kimura, T., Sakakibara, S., Song, X. J., Maruta, H. and Muramatsu, T. (1994) Localization of heparin-binding, neurite outgrowth and antigenic regions in midkine molecule. Biochem. Biophys. Res. Commun. 203, 1131-1139
64. Kilpelainen, I., Kaksonen, M., Avikainen, H., Fath, M., Linhardt, R. J., Raulo, E. and Rauvala, H. (2000) Heparin-binding growth-associated molecule contains two heparin-binding β-sheet domains that are homologous to the thrombospondin type I repeat. J. Biol. Chem. 275, 13564-13570
65. Englund, C., Birve, A., Falileeva, L., Grabbe, C. and Palmer, R. H. (2006) Miple1 and miple2 encode a family of MK/PTN homologues in Drosophila melanogaster. Dev. Genes Evol. 216, 10-18
66. Pulford, K., Morris, S. W. and Turturro, F. (2004) Anaplastic lymphoma kinase proteins in growth control and cancer. J. Cell Physiol. 199, 330-358
67. Bilsland, J. G., Wheeldon, A., Mead, A., Znamenskiy, P., Almond, S., Waters, K. A., Thakur, M., Beaumont, V., Bonnert, T. P., Heavens, R. et al. (2008) Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology 33, 685-700
68. Nakamura, E., Kadomatsu, K., Yuasa, S., Muramatsu, H., Mamiya, T., Nabeshima, T., Fan, Q. W., Ishiguro, K., Igakura, T., Matsubara, S. et al. (1998) Disruption of the midkine gene (Mdk) resulted in altered expression of a calcium binding protein in the hippocampus of infant mice and their abnormal behaviour. Genes Cells 3, 811-822
69. Fan, Q. W., Muramatsu, T. and Kadomatsu, K. (2000) Distinct expression of midkine and pleiotrophin in the spinal cord and placental tissues during early mouse development. Dev. Growth Differ. 42, 113-119
70. Matsumoto, K., Wanaka, A., Mori, T., Taguchi, A., Ishii, N., Muramatsu, H., Muramatsu, T. and Tohyama, M. (1994) Localization of pleiotrophin and midkine in the postnatal developing cerebellum. Neurosci. Lett. 178, 216-220
71. Mitsiadis, T. A., Salmivirta, M., Muramatsu, T., Muramatsu, H., Rauvala, H., Lehtonen, E., Jalkanen, M. and Thesleff, I. (1995) Expression of the heparin-binding cytokines, midkine (MK) and HB-GAM (pleiotrophin) is associated with epithelial-mesenchymal interactions during fetal development and organogenesis. Development 121, 37-51
72. Vanderwinden, J. M., Mailleux, P., Schiffmann, S. N. and Vanderhaeghen, J. J. (1992) Cellular distribution of the new growth factor pleiotrophin (HB-GAM) mRNA in developing and adult rat tissues. Anat. Embryol. 186, 387-406
73. Herradon, G., Ezquerra, L., Nguyen, T., Silos-Santiago, I. and Deuel, T. F. (2005) Midkine regulates pleiotrophin organ-specific gene expression: evidence for transcriptional regulation and functional redundancy within the pleiotrophin/midkine developmental gene family. Biochem. Biophys. Res. Commun. 333, 714-721
74. Muramatsu, H., Zou, P., Kurosawa, N., Ichihara-Tanaka, K., Maruyama, K., Inoh, K., Sakai, T., Chen, L., Sato, M. and Muramatsu, T. (2006) Female infertility in mice deficient in midkine and pleiotrophin, which form a distinct family of growth factors. Genes Cells 11, 1405-1417
75. Zou, P., Muramatsu, H., Sone, M., Hayashi, H., Nakashima, T. and Muramatsu, T. (2006) Mice doubly deficient in the midkine and pleiotrophin genes exhibit deficits in the expression of β-tectorin gene and in auditory response. Lab. Invest. 86, 645-653
76. Bernards, A. and de la Monte, S. M. (1990) The ltk receptor tyrosine kinase is expressed in pre-B lymphocytes and cerebral neurons and uses a non-AUG translational initiator. EMBO J. 9, 2279-2287
77. Yamada, S., Nomura, T., Takano, K., Fujita, S., Miyake, M. and Miyake, J. (2008) Expression of a chimeric CSF1R-LTK mediates ligand-dependent neurite outgrowth. NeuroRep. 19, 1733-1738
78. Griffin, C. A., Hawkins, A. L., Dvorak, C., Henkle, C., Ellingham, T. and Perlman, E. J. (1999) Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 59, 2776-2780
79. Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H. et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566
80. Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y. et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203
81. Arber, D. A., Sun, L. H. and Weiss, L. M. (1996) Detection of the t(2;5)(p23;q35) chromosomal translocation in large B-cell lymphomas other than anaplastic large cell lymphoma. Hum. Pathol. 27, 590-594
82. Du, X. L., Hu, H., Lin, D. C., Xia, S. H., Shen, X. M., Zhang, Y., Luo, M. L., Feng, Y. B., Cai, Y., Xu, X. et al. (2007) Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. J. Mol. Med. 85, 863-875
83. Jazii, F. R., Najafi, Z., Malekzadeh, R., Conrads, T. P., Ziaee, A. A., Abnet, C., Yazdznbod, M., Karkhane, A. A. and Salekdeh, G. H. (2006) Identification of squamous cell carcinoma associated proteins by proteomics and loss of β tropomyosin expression in esophageal cancer. World J. Gastroenterol. 12, 7104-7112
84. Perez-Pinera, P., Chang, Y., Astudillo, A., Mortimer, J. and Deuel, T. F. (2007) Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer. Biochem. Biophys. Res. Commun. 358, 399-403
85. Delsol, G., Lamant, L., Mariame, B., Pulford, K., Dastugue, N., Brousset, P., Rigal-Huguet, F., al Saati, T., Cerretti, D. P., Morris, S. W. and Mason, D. Y. (1997) A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 89, 1483-1490
86. Cessna, M. H., Zhou, H., Sanger, W. G., Perkins, S. L., Tripp, S., Pickering, D., Daines, C. and Coffin, C. M. (2002) Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod. Pathol. 15, 931-938
87. Pillay, K., Govender, D. and Chetty, R. (2002) ALK protein expression in rhabdomyosarcomas. Histopathology 41, 461-467
88. Lamant, L., Pulford, K., Bischof, D., Morris, S. W., Mason, D. Y., Delsol, G. and Mariame, B. (2000) Expression of the ALK tyrosine kinase gene in neuroblastoma. Am. J. Pathol. 156, 1711-1721
89. Miyake, I., Hakomori, Y., Shinohara, A., Gamou, T., Saito, M., Iwamatsu, A. and Sakai, R. (2002) Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 21, 5823-5834
90. Osajima-Hakomori, Y., Miyake, I., Ohira, M., Nakagawara, A., Nakagawa, A. and Sakai, R. (2005) Biological role of anaplastic lymphoma kinase in neuroblastoma. Am. J. Pathol. 167, 213-222
91. Corao, D., Biegel, J. A., Coffin, C. M., Barr, F. G., Wainwright, L. M., Ernst, L. M., Choi, J. K., Zhang, P. J. and Pawel, B. (2008) ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status, Pediatr. Dev. Pathol., doi: 10.2350/08-03-0434.1
92. Li, X. Q., Hisaoka, M., Shi, D. R., Zhu, X. Z. and Hashimoto, H. (2004) Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases. Hum. Pathol. 35, 711-721
93. Caren, H., Abel, F., Kogner, P. and Martinsson, T. (2008) High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem. J. 416, 153-159
94. Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T. et al. (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974
95. George, R. E., Sanda, T., Hanna, M., Frohling, S., Luther, 2nd, W., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P. et al. (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975-978
96. Janoueix-Lerosey, I., Lequin, D., Brugieres, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G. et al. (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970
97. Mosse, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P. et al. (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935
98. Stein, H., Mason, D. Y., Gerdes, J., O'Connor, N., Wainscoat, J., Pallesen, G., Gatter, K., Falini, B., Delsol, G., Lemke, H. et al. (1985) The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66, 848-858
99. + anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96, 3681-3695
100. + anaplastic large-cell lymphoma. Blood 110, 2259-2267
101. Swerdlow, S. H., Campo, E., Harris, N. L., Jaffe, E. S., Pileri, S. A., Stein, H., Thiele, J. and Vardiman, J. W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphiod Tissues, International Agency for Research on Cancer, Lyon
102. + ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111, 5496-5504
103. Gascoyne, R. D., Aoun, P., Wu, D., Chhanabhai, M., Skinnider, B. F., Greiner, T. C., Morris, S. W., Connors, J. M., Vose, J. M., Viswanatha, D. S. et al. (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93, 3913-3921
104. Shiota, M., Nakamura, S., Ichinohasama, R., Abe, M., Akagi, T., Takeshita, M., Mori, N., Fujimoto, J., Miyauchi, J., Mikata, A. et al. (1995) Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 86, 1954-1960
105. + lymphoma: clinico-pathological findings and outcome. Blood 93, 2697-2706
106. Brugieres, L., Quartier, P., Le Deley, M. C., Pacquement, H., Perel, Y., Bergeron, C., Schmitt, C., Landmann, J., Patte, C., Terrier-Lacombe, M. J. et al. (2000) Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children-a report from the French Society of Pediatric Oncology. Ann. Oncol. 11, 53-58
107. ten Berge, R. L., Meijer, C. J., Dukers, D. F., Kummer, J. A., Bladergroen, B. A., Vos, W., Hack, C. E., Ossenkoppele, G. J. and Oudejans, J. J. (2002) Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 99, 4540-4546
108. Khoury, J. D., Medeiros, L. J., Rassidakis, G. Z., Yared, M. A., Tsioli, P., Leventaki, V., Schmitt-Graeff, A., Herling, M., Amin, H. M. and Lai, R. (2003) Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALKanaplastic large cell lymphoma. Clin. Cancer Res. 9, 3692-3699
109. Schlette, E. J., Medeiros, L. J., Goy, A., Lai, R. and Rassidakis, G. Z. (2004) Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J. Clin. Oncol. 22, 1682-1688
110. Rassidakis, G. Z., Goy, A., Medeiros, L. J., Jiang, Y., Thomaides, A., Remache, Y., Cabanillas, F., Sarris, A. H. and Gilles, F. (2003) Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma. Clin. Cancer Res. 9, 2213-2220
111. Hattrup, C. L. and Gendler, S. J. (2008) Structure and function of the cell surface (tethered) mucins. Annu. Rev. Physiol. 70, 431-457
112. Trumper, L., Pfreundschuh, M., Bonin, F. V. and Daus, H. (1998) Detection of the t(2;5)-associated NPM/ALK fusion cDNA in peripheral blood cells of healthy individuals. Br. J. Haematol. 103, 1138-1144
113. Maes, B., Vanhentenrijk, V., Wlodarska, I., Cools, J., Peeters, B., Marynen, P. and de Wolf-Peeters, C. (2001) The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells. Am. J. Pathol. 158, 2185-2193
114. Okuwaki, M. (2008) The structure and functions of NPM1/Nucleophsmin/B23, a multifunctional nucleolar acidic protein. J. Biochem. 143, 441-448
115. Fujimoto, J., Shiota, M., Iwahara, T., Seki, N., Satoh, H., Mori, S. and Yamamoto, T. (1996) Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc. Natl. Acad. Sci. U.S.A. 93, 4181-4186
116. Bischof, D., Pulford, K., Mason, D. Y. and Morris, S. W. (1997) Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol. Cell. Biol. 17, 2312-2325
117. Cools, J., Wlodarska, I., Somers, R., Mentens, N., Pedeutour, F., Maes, B., De Wolf-Peeters, C., Pauwels, P., Hagemeijer, A. and Marynen, P. (2002) Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 34, 354-362
118. Hernandez, L., Bea, S., Bellosillo, B., Pinyol, M., Falini, B., Carbone, A., Ott, G., Rosenwald, A., Fernandez, A., Pulford, K. et al. (2002) Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. Am. J. Pathol. 160, 1487-1494
119. Hernandez, L., Pinyol, M., Hernandez, S., Bea, S., Pulford, K., Rosenwald, A., Lamant, L., Falini, B., Ott, G., Mason, D. Y. et al. (1999) TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 94, 3265-3268
120. Tort, F., Pinyol, M., Pulford, K., Roncador, G., Hernandez, L., Nayach, I., Kluin-Nelemans, H. C., Kluin, P., Touriol, C., Delsol, G. et al. (2001) Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab. Invest. 81, 419-426
121. Lamant, L., Dastugue, N., Pulford, K., Delsol, G. and Mariame, B. (1999) A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 93, 3088-3095
122. Siebert, R., Gesk, S., Harder, L., Steinemann, D., Grote, W., Schlegelberger, B., Tiemann, M., Wlodarska, I. and Schemmel, V. (1999) Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma. Blood 94, 3614-3617
123. Meech, S. J., McGavran, L., Odom, L. F., Liang, X., Meltesen, L., Gump, J., Wei, Q., Carlsen, S. and Hunger, S. P. (2001) Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4-anaplastic lymphoma kinase gene fusion. Blood 98, 1209-1216
124. Ma, Z., Cools, J., Marynen, P., Cui, X., Siebert, R., Gesk, S., Schlegelberger, B., Peeters, B., De Wolf-Peeters, C., Wlodarska, I. and Morris, S. W. (2000) Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 95, 2144-2149
125. Trinei, M., Lanfrancone, L., Campo, E., Pulford, K., Mason, D. Y., Pelicci, P. G. and Falini, B. (2000) A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res. 60, 793-798
126. Colleoni, G. W., Bridge, J. A., Garicochea, B., Liu, J., Filippa, D. A. and Ladanyi, M. (2000) ATIC-ALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am. J. Pathol. 156, 781-789
127. Lamant, L., Gascoyne, R. D., Duplantier, M. M., Armstrong, F., Raghab, A., Chhanabhai, M., Rajcan-Separovic, E., Raghab, J., Delsol, G. and Espinos, E. (2003) Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer 37, 427-432
128. Touriol, C., Greenland, C., Lamant, L., Pulford, K., Bernard, F., Rousset, T., Mason, D. Y. and Delsol, G. (2000) Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 95, 3204-3207
129. Beardsley, G. P., Rayl, E. A., Gunn, K., Moroson, B. A., Seow, H., Anderson, K. S., Vergis, J., Fleming, K., Worland, S., Condon, B. and Davies, J. (1998) Structure and functional relationships in human pur H. Adv. Exp. Med. Biol. 431, 221-226
130. Bai, R. Y., Ouyang, T., Miething, C., Morris, S. W., Peschel, C. and Duyster, J. (2000) Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96, 4319-4327
131. Polgar, D., Leisser, C., Maier, S., Strasser, S., Ruger, B., Dettke, M., Khorchide, M., Simonitsch, I., Cerni, C. and Krupitza, G. (2005) Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K. Mutat. Res. 570, 9-15
132. Slupianek, A., Nieborowska-Skorska, M., Hoser, G., Morrione, A., Majewski, M., Xue, L., Morris, S. W., Wasik, M. A. and Skorski, T. (2001) Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 61, 2194-2199
133. Gu, T. L., Tothova, Z., Scheijen, B., Griffin, J. D., Gilliland, D. G. and Sternberg, D. W. (2004) NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood 103, 4622-4629
134. Rassidakis, G. Z., Feretzaki, M., Atwell, C., Grammatikakis, I., Lin, Q., Lai, R., Claret, F. X., Medeiros, L. J. and Amin, H. M. (2005) Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood 105, 827-829
135. Vega, F., Medeiros, L. J., Leventaki, V., Atwell, C., Cho-Vega, J. H.,
136. Marzec, M., Kasprzycka, M., Liu, X., El-Salem, M., Halasa, K., Raghunath, P. N., Bucki, R., Wlodarski, P. and Wasik, M. A. (2007) Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene 26, 5606-5614
137. Crockett, D. K., Lin, Z., Elenitoba-Johnson, K. S. and Lim, M. S. (2004) Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene 23, 2617-2629
138. Marzec, M., Kasprzycka, M., Liu, X., Raghunath, P. N., Wlodarski, P. and Wasik, M. A. (2007) Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene 26, 813-821
139. Amin, H. M., McDonnell, T. J., Ma, Y., Lin, Q., Fujio, Y., Kunisada, K., Leventaki, V., Das, P., Rassidakis, G. Z., Cutler, C. et al. (2004) Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 23, 5426-5434
140. Zamo, A., Chiarle, R., Piva, R., Howes, J., Fan, Y., Chilosi, M., Levy, D. E. and Inghirami, G. (2002) Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21, 1038-1047
141. Zhang, Q., Raghunath, P. N., Xue, L., Majewski, M., Carpentieri, D. F., Odum, N., Morris, S., Skorski, T. and Wasik, M. A. (2002) Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J. Immunol. 168, 466-474
142. Galkin, A. V., Melnick, J. S., Kim, S., Hood, T. L., Li, N., Li, L., Xia, G., Steensma, R., Chopiuk, G., Jiang, J. et al. (2007) Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc. Natl. Acad. Sci. U.S.A. 104, 270-275
143. Marzec, M., Kasprzycka, M., Ptasznik, A., Wlodarski, P., Zhang, Q., Odum, N. and Wasik, M. A. (2005) Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab. Invest. 85, 1544-1554
144. Wan, W., Albom, M. S., Lu, L., Quail, M. R., Becknell, N. C., Weinberg, L. R., Reddy, D. R., Holskin, B. P., Angeles, T. S., Underiner, T. L. et al. (2006) Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 107, 1617-1623
145. Amin, H. M., Medeiros, L. J., Ma, Y., Feretzaki, M., Das, P., Leventaki, V., Rassidakis, G. Z., O'Connor, S. L., McDonnell, T. J. and Lai, R. (2003) Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 22, 5399-5407
146. Shi, X., Franko, B., Frantz, C., Amin, H. M. and Lai, R. (2006) JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. Br. J. Haematol. 135, 26-32
147. Lai, R., Rassidakis, G. Z., Lin, Q., Atwell, C., Medeiros, L. J. and Amin, H. M. (2005) Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma. Hum. Pathol. 36, 939-944
148. Qiu, L., Lai, R., Lin, Q., Lau, E., Thomazy, D. M., Calame, D., Ford, R. J., Kwak, L. W., Kirken, R. A. and Amin, H. M. (2006) Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood 108, 2407-2415
149. Han, Y., Amin, H. M., Franko, B., Frantz, C., Shi, X. and Lai, R. (2006) Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood 108, 2796-2803
150. Chiarle, R., Simmons, W. J., Cai, H., Dhall, G., Zamo, A., Raz, R., Karras, J. G., Levy, D. E. and Inghirami, G. (2005) Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 11, 623-629
151. Khoury, J. D., Rassidakis, G. Z., Medeiros, L. J., Amin, H. M. and Lai, R. (2004) Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma. Blood 104, 1580-1581
152. Nieborowska-Skorska, M., Slupianek, A., Xue, L., Zhang, Q., Raghunath, P. N., Hoser, G., Wasik, M. A., Morris, S. W. and Skorski, T. (2001) Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res. 61, 6517-6523
153. Zhang, Q., Wang, H. Y., Liu, X. and Wasik, M. A. (2007) STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nat. Med. 13, 1341-1348
154. Ambrogio, C., Voena, C., Manazza, A. D., Martinengo, C., Costa, C., Kirchhausen, T., Hirsch, E., Inghirami, G. and Chiarle, R. (2008) The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res. 68, 8899-8907
155. Colomba, A., Courilleau, D., Ramel, D., Billadeau, D. D., Espinos, E., Delsol, G., Payrastre, B. and Gaits-Iacovoni, F. (2008) Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas. Oncogene 27, 2728-2736
156. Voena, C., Conte, C., Ambrogio, C., Boeri Erba, E., Boccalatte, F., Mohammed, S., Jensen, O. N., Palestro, G., Inghirami, G. and Chiarle, R. (2007) The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res. 67, 4278-4286
157. Cussac, D., Greenland, C., Roche, S., Bai, R. Y., Duyster, J., Morris, S. W., Delsol, G., Allouche, M. and Payrastre, B. (2004) Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 103, 1464-1471
158. Bassermann, F., von Klitzing, C., Munch, S., Bai, R. Y., Kawaguchi, H., Morris, S. W., Peschel, C. and Duyster, J. (2005) NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry. Cell 122, 45-57
159. Ouyang, T., Bai, R. Y., Bassermann, F., von Klitzing, C., Klumpen, S., Miething, C., Morris, S. W., Peschel, C. and Duyster, J. (2003) Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA). J. Biol. Chem. 278, 30028-30036
160. Turner, S. D., Tooze, R., Maclennan, K. and Alexander, D. R. (2003) Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene 22, 7750-7761
161. Leventaki, V., Drakos, E., Medeiros, L. J., Lim, M. S., Elenitoba-Johnson, K. S., Claret, F. X. and Rassidakis, G. Z. (2007) NPM-ALK oncogenic kinase promotes cell cycle progression through activation of JNK/cJun signaling in anaplastic large cell lymphoma. Blood 110, 1621-1630
162. Singh, R. R., Cho-Vega, J. H., Davuluri, Y., Ma, S., Kasbidi, F., Milito, C., Lennon, P. A., Drakos, E., Medeiros, L. J., Luthra, R. and Vega, F. (2009) Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. Cancer Res. 69, 2550-2558
163. Boccalatte, F. E., Voena, C., Riganti, C., Bosia, A., D'Amico, L., Riera, L., Cheng, M., Ruggeri, B., Jensen, O. N., Goss, V. L. et al. (2008) The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood 113, 2776-2790
164. Piva, R., Pellegrino, E., Mattioli, M., Agnelli, L., Lombardi, L., Boccalatte, F., Costa, G., Ruggeri, B. A., Cheng, M., Chiarle, R. et al. (2006) Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J. Clin. Invest. 116, 3171-3182
165. Lamant, L., de Reynies, A., Duplantier, M. M., Rickman, D. S., Sabourdy, F., Giuriato, S., Brugieres, L., Gaulard, P., Espinos, E. and Delsol, G. (2007) Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 109, 2156-2164
166. Rush, J., Moritz, A., Lee, K. A., Guo, A., Goss, V. L., Spek, E. J., Zhang, H., Zha, X. M., Polakiewicz, R. D. and Comb, M. J. (2005) Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat. Biotechnol. 23, 94-101
167. Sjostrom, C., Seiler, C., Crockett, D. K., Tripp, S. R., Elenitoba Johnson, K. S. and Lim, M. S. (2007) Global proteome profiling of NPM/ ALK-positive anaplastic large cell lymphoma. Exp. Haematol. 35, 1240-1248
168. Wu, F., Wang, P., Young, L. C., Lai, R. and Li, L. (2009) Proteome-wide identification of novel binding partners to the oncogenic fusion gene protein, NPM-ALK, using tandem affinity purification and mass spectrometry. Am. J. Pathol. 174, 361-370
169. Armstrong, F., Duplantier, M. M., Trempat, P., Hieblot, C., Lamant, L., Espinos, E., Racaud-Sultan, C., Allouche, M., Campo, E., Delsol, G. and Touriol, C. (2004) Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene 23, 6071-6082
170. Momose, S., Tamaru, J., Kishi, H., Mikata, I., Mori, M., Toyozumi, Y. and Itoyama, S. (2009) Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion. Hum. Pathol. 40, 75-82
171. Gleason, B. C. and Hornick, J. L. (2008) Inflammatory myofibroblastic tumours: where are we now? J. Clin. Pathol. 61, 428-437
172. Umiker, W. O. and Iverson, L. (1954) Postinflammatory tumors of the lung; report of four cases simulating xanthoma, fibroma, or plasma cell tumor. J. Thorac. Surg. 28, 55-63
173. Coffin, C. M., Watterson, J., Priest, J. R. and Dehner, L. P. (1995) Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am. J. Surg. Pathol. 19, 859-872
174. Lawrence, B., Perez-Atayde, A., Hibbard, M. K., Rubin, B. P., Dal Cin, P., Pinkus, J. L., Pinkus, G. S., Xiao, S., Yi, E. S., Fletcher, C. D. and Fletcher, J. A. (2000) TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am. J. Pathol. 157, 377-384
175. Debiec-Rychter, M., Marynen, P., Hagemeijer, A. and Pauwels, P. (2003) ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 38, 187-190
176. Patel, A. S., Murphy, K. M., Hawkins, A. L., Cohen, J. S., Long, P. P., Perlman, E. J. and Griffin, C. A. (2007) RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors. Cancer Genet. Cytogenet. 176, 107-114
177. Bridge, J. A., Kanamori, M., Ma, Z., Pickering, D., Hill, D. A., Lydiatt, W., Lui, M. Y., Colleoni, G. W., Antonescu, C. R., Ladanyi, M. and Morris, S. W. (2001) Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am. J. Pathol. 159, 411-415
178. Debelenko, L. V., Arthur, D. C., Pack, S. D., Helman, L. J., Schrump, D. S. and Tsokos, M. (2003) Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab. Invest. 83, 1255-1265
179. Ma, Z., Hill, D. A., Collins, M. H., Morris, S. W., Sumegi, J., Zhou, M., Zuppan, C. and Bridge, J. A. (2003) Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 37, 98-105
180. Panagopoulos, I., Nilsson, T., Domanski, H. A., Isaksson, M., Lindblom, P., Mertens, F. and Mandahl, N. (2006) Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int. J. Cancer 118, 1181-1186
181. Coffin, C. M., Patel, A., Perkins, S., Elenitoba-Johnson, K. S., Perlman, E. and Griffin, C. A. (2001) ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod. Pathol. 14, 569-576
182. Cook, J. R., Dehner, L. P., Collins, M. H., Ma, Z., Morris, S. W., Coffin, C. M. and Hill, D. A. (2001) Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am. J. Surg. Pathol. 25, 1364-1371
183. Coffin, C. M., Hornick, J. L. and Fletcher, C. D. (2007) Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am. J. Surg. Pathol. 31, 509-520
184. Chun, Y. S., Wang, L., Nascimento, A. G., Moir, C. R. and Rodeberg, D. A. (2005) Pediatric inflammatory myofibroblastic tumor: anaplastic lymphoma kinase (ALK) expression and prognosis. Ped. Blood Cancer 45, 796-801
185. Jemal, A., Clegg, L. X., Ward, E., Ries, L. A., Wu, X., Jamison, P. M., Wingo, P. A., Howe, H. L., Anderson, R. N. and Edwards, B. K. (2004) Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101, 3-27
186. Kamangar, F., Dores, G. M. and Anderson, W. F. (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24, 2137-2150
187. Perner, S., Wagner, P. L., Demichelis, F., Mehra, R., Lafargue, C. J., Moss, B. J., Arbogast, S., Soltermann, A., Weder, W., Giordano, T. J. et al. (2008) EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 10, 298-302
188. Inamura, K., Takeuchi, K., Togashi, Y., Nomura, K., Ninomiya, H., Okui, M., Satoh, Y., Okumura, S., Nakagawa, K., Soda, M. et al. (2008) EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J. Thorac. Oncol. 3, 13-17
189. Fukuyoshi, Y., Inoue, H., Kita, Y., Utsunomiya, T., Ishida, T. and Mori, M. (2008) EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br. J. Cancer 98, 1536-1539
190. Shinmura, K., Kageyama, S., Tao, H., Bunai, T., Suzuki, M., Kamo, T., Takamochi, K., Suzuki, K., Tanahashi, M., Niwa, H. et al. (2008) EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 61, 163-169
191. Koivunen, J. P., Mermel, C., Zejnullahu, K., Murphy, C., Lifshits, E., Holmes, A. J., Choi, H. G., Kim, J., Chiang, D., Thomas, R. et al. (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 14, 4275-4283
192. Wong, D. W., Leung, E. L., So, K. K., Tam, I. Y., Sihoe, A. D., Cheng, L. C., Ho, K. K., Au, J. S., Chung, L. P. and Pik Wong, M. (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS, Cancer, doi: 10.1002/cncr.24181
193. Martelli, M. P., Sozzi, G., Hernandez, L., Pettirossi, V., Navarro, A., Conte, D., Gasparini, P., Perrone, F., Modena, P., Pastorino, U. et al. (2009) EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am. J. Pathol. 174, 661-670
194. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500
195. Soda, M., Takada, S., Takeuchi, K., Choi, Y. L., Enomoto, M., Ueno, T., Haruta, H., Hamada, T., Yamashita, Y., Ishikawa, Y. et al. (2008) A mouse model for EML4-ALK-positive lung cancer. Proc. Natl. Acad. Sci. U.S.A. 105, 19893-19897
196. Zou, H. Y., Li, Q., Lee, J. H., Arango, M. E., McDonnell, S. R., Yamazaki, S., Koudriakova, T. B., Alton, G., Cui, J. J., Kung, P. P. et al. (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408-4417
197. Christensen, J. G., Zou, H. Y., Arango, M. E., Li, Q., Lee, J. H., McDonnell, S. R., Yamazaki, S., Alton, G. R., Mroczkowski, B. and Los, G. (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 6, 3314-3322
198. McDermott, U., Iafrate, A. J., Gray, N. S., Shioda, T., Classon, M., Maheswaran, S., Zhou, W., Choi, H. G., Smith, S. L., Dowell, L. et al. (2008) Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 68, 3389-3395
199. Reichard, K. K., McKenna, R. W. and Kroft, S. H. (2007) ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod. Pathol. 20, 310-319
200. Stachurski, D., Miron, P. M., Al-Homsi, S., Hutchinson, L., Harris, N. L., Woda, B. and Wang, S. A. (2007) Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3′ ALK gene insertion to chromosome 4 q22-24. Hum. Pathol. 38, 940-945
201. Lee, H. W., Kim, K., Kim, W. and Ko, Y. H. (2008) ALK-positive diffuse large B-cell lymphoma: report of three cases. Hematol. Oncol. 26, 108-113
202. Choung, H. S., Kim, H. J., Kim, W. S., Kim, K. and Kim, S. H. (2008) [Cytomorphology and molecular characterization of CLTC-ALK rearrangement in 2 cases of ALK-positive diffuse large B-cell lymphoma with extensive bone marrow involvement]. Korean J. Lab. Med. 28, 89-94
203. Onciu, M., Behm, F. G., Downing, J. R., Shurtleff, S. A., Raimondi, S. C., Ma, Z., Morris, S. W., Kennedy, W., Jones, S. C. and Sandlund, J. T. (2003) ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood 102, 2642-2644
204. Adam, P., Katzenberger, T., Seeberger, H., Gattenlohner, S., Wolf, J., Steinlein, C., Schmid, M., Muller-Hermelink, H. K. and Ott, G. (2003) A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am. J. Surg. Pathol. 27, 1473-1476
205. Grzelinski, M., Steinberg, F., Martens, T., Czubayko, F., Lamszus, K. and Aigner, A. (2009) Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia 11, 145-156
206. Garver, Jr, R. I., Radford, D. M., Donis-Keller, H., Wick, M. R. and Milner, P. G. (1994) Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 74, 1584-1590
207. Riegel, A. T. and Wellstein, A. (1994) The potential role of the heparin-binding growth factor pleiotrophin in breast cancer. Breast Cancer Res. Treatment 31, 309-314
208. Zhang, N., Zhong, R., Wang, Z. Y. and Deuel, T. F. (1997) Human breast cancer growth inhibited in vivo by a dominant negative pleiotrophin mutant. J. Biol. Chem. 272, 16733-16736
209. Maris, J. M., Hogarty, M. D., Bagatell, R. and Cohn, S. L. (2007) Neuroblastoma. Lancet 369, 2106-2120
210. Brodeur, G. M. (2003) Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3, 203-216
211. Kuefer, M. U., Look, A. T., Pulford, K., Behm, F. G., Pattengale, P. K., Mason, D. Y. and Morris, S. W. (1997) Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 90, 2901-2910
212. Lange, K., Uckert, W., Blankenstein, T., Nadrowitz, R., Bittner, C., Renauld, J. C., van Snick, J., Feller, A. C. and Merz, H. (2003) Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene 22, 517-527
213. Chiarle, R., Gong, J. Z., Guasparri, I., Pesci, A., Cai, J., Liu, J., Simmons, W. J., Dhall, G., Howes, J., Piva, R. and Inghirami, G. (2003) NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 101, 1919-1927
214. Jager, R., Hahne, J., Jacob, A., Egert, A., Schenkel, J., Wernert, N., Schorle, H. and Wellmann, A. (2005) Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas. Anticancer Res. 25, 3191-3196
215. Turner, S. D. and Alexander, D. R. (2005) What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? Leukemia 19, 1128-1134
216. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J. and Lydon, N. B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566
217. Druker, B. J. (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 112, 4808-4817
218. Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J. and Lydon, N. B. (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295, 139-145
219. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Regenass, U. and Lydon, N. B. (1995) Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. U.S.A. 92, 2558-2562
220. Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M. et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577-580
221. Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M. et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480
222. van Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., Donato di Paola, E., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M. et al. (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358, 1421-1423
223. Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S., Capdeville, R., Dimitrijevic, S., Druker, B. and Demetri, G. D. (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344, 1052-1056
224. Arora, A. and Scholar, E. M. (2005) Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315, 971-979
225. Takahashi, I., Saitoh, Y., Yoshida, M., Sano, H., Nakano, H., Morimoto, M. and Tamaoki, T. (1989) UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. J. Antibiotics 42, 571-576
226. Graves, P. R., Yu, L., Schwarz, J. K., Gales, J., Sausville, E. A., O'Connor, P. M. and Piwnica-Worms, H. (2000) The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. 275, 5600-5605
227. Sausville, E. A., Arbuck, S. G., Messmann, R., Headlee, D., Bauer, K. S., Lush, R. M., Murgo, A., Figg, W. D., Lahusen, T., Jaken, S. et al. (2001) Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J. Clin. Oncol. 19, 2319-2333
228. Gunby, R. H., Tartari, C. J., Porchia, F., Donella-Deana, A., Scapozza, L. and Gambacorti-Passerini, C. (2005) An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase. Haematologica 90, 988-990
229. Li, R., Xue, L., Zhu, T., Jiang, Q., Cui, X., Yan, Z., McGee, D., Wang, J., Gantla, V. R., Pickens, J. C. et al. (2006) Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase. J. Med. Chem. 49, 1006-1015
230. Li, R. and Morris, S. W. (2008) Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med. Res. Rev. 28, 372-412
231. Grzelinski, M., Bader, N., Czubayko, F. and Aigner, A. (2005) Ribozyme-targeting reveals the rate-limiting role of pleiotrophin in glioblastoma. Int. J. Cancer 117, 942-951
232. Hubinger, G., Wehnes, E., Xue, L., Morris, S. W. and Maurer, U. (2003) Hammerhead ribozyme-mediated cleavage of the fusion transcript NPM-ALK associated with anaplastic large-cell lymphoma. Exp. Hematol. 31, 226-233
233. Piva, R., Chiarle, R., Manazza, A. D., Taulli, R., Simmons, W., Ambrogio, C., D'Escamard, V., Pellegrino, E., Ponzetto, C., Palestro, G. and Inghirami, G. (2006) Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 107, 689-697
234. Chiarle, R., Martinengo, C., Mastini, C., Ambrogio, C., D'Escamard, V., Forni, G. and Inghirami, G. (2008) The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat. Med. 14, 676-680
235. + lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res. 62, 1559-1566
236. Hudis, C. A. (2007) Trastuzumab: mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51
237. De Paepe, P., Baens, M., van Krieken, H., Verhasselt, B., Stul, M., Simons, A., Poppe, B., Laureys, G., Brons, P., Vandenberghe, P. et al. (2003) ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 102, 2638-2641